These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 26551483

  • 41. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes.
    Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B.
    Clin Ther; 2006 Oct; 28(10):1569-81. PubMed ID: 17157113
    [Abstract] [Full Text] [Related]

  • 42. Effect of baseline glycosylated hemoglobin A1c on glycemic control and diabetes management following initiation of once-daily insulin detemir in real-life clinical practice.
    Caputo S, Andersen H, Kaiser M, Karnieli E, Meneghini LF, Svendsen AL, SOLVE Study Group.
    Endocr Pract; 2013 Oct; 19(3):462-70. PubMed ID: 23337147
    [Abstract] [Full Text] [Related]

  • 43. Exploring the characteristics of suboptimally controlled patients after 24weeks of basal insulin treatment: An individualized approach to intensification.
    Khunti K, Damci T, Husemoen LL, Babu V, Liebl A.
    Diabetes Res Clin Pract; 2017 Jan; 123():209-217. PubMed ID: 28061430
    [Abstract] [Full Text] [Related]

  • 44. PREDICTIVE- a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort.
    Lüddeke HJ, Sreenan S, Aczel S, Maxeiner S, Yenigun M, Kozlovski P, Gydesen H, Dornhorst A, PREDICTIVE Study Group.
    Diabetes Obes Metab; 2007 May; 9(3):428-34. PubMed ID: 17391171
    [Abstract] [Full Text] [Related]

  • 45. COMPARISON OF EFFICACY AND SAFETY OF GLARGINE AND DETEMIR INSULIN IN THE MANAGEMENT OF INPATIENT HYPERGLYCEMIA AND DIABETES.
    Galindo RJ, Davis GM, Fayfman M, Reyes-Umpierrez D, Alfa D, Peng L, Tamler R, Pasquel FJ, Umpierrez GE.
    Endocr Pract; 2017 Sep; 23(9):1059-1066. PubMed ID: 28683239
    [Abstract] [Full Text] [Related]

  • 46. Impact of Insulin Detemir Administration Time on Hypoglycemia Rates in Hospitalized Patients.
    Grelle JL, Kutter SN, Giruzzi ME, Tawwater JC.
    Pharmacotherapy; 2017 Dec; 37(12):1523-1529. PubMed ID: 29028123
    [Abstract] [Full Text] [Related]

  • 47. Clinical experience with insulin detemir: results from the Indonesian cohort of the international A₁chieve study.
    Soewondo P, Kshanti IA, Pramono RB, Langi YA, Dalem-Pemayun TG.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S47-53. PubMed ID: 23647719
    [Abstract] [Full Text] [Related]

  • 48. A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: Effective switch from intensive insulin therapy to the once-daily injection in patients with well-controlled type 2 diabetes.
    Inoue Y, Nakamura A, Kondo Y, Hamano K, Satoh S, Terauchi Y.
    J Clin Pharmacol; 2015 Jul; 55(7):831-8. PubMed ID: 25677642
    [Abstract] [Full Text] [Related]

  • 49. The effectiveness, safety and epidemiology of the use of acarbose in the treatment of patients with type II diabetes mellitus. A model of medicine-based evidence.
    Scorpiglione N, Belfiglio M, Carinci F, Cavaliere D, De Curtis A, Franciosi M, Mari E, Sacco M, Tognoni G, Nicolucci A.
    Eur J Clin Pharmacol; 1999 Jun; 55(4):239-49. PubMed ID: 10424314
    [Abstract] [Full Text] [Related]

  • 50. Basal insulin initiation in primary vs. specialist care: similar glycaemic control in two different patient populations.
    Orozco-Beltran D, Pan C, Svendsen AL, Faerch L, Caputo S, SOLVE Study Group.
    Int J Clin Pract; 2016 Mar; 70(3):236-43. PubMed ID: 26916450
    [Abstract] [Full Text] [Related]

  • 51. Comparison of treatment with insulin detemir and NPH in women with gestational diabetes mellitus: glycemic control and pregnancy outcomes. A retrospective study.
    Kazakou P, Paschou SA, Mitropoulou M, Vasileiou V, Sarantopoulou V, Anastasiou E.
    Hormones (Athens); 2023 Dec; 22(4):695-701. PubMed ID: 37775682
    [Abstract] [Full Text] [Related]

  • 52. Initiation of once daily insulin detemir is not associated with weight gain in patients with type 2 diabetes mellitus: results from an observational study.
    Yale JF, Damci T, Kaiser M, Karnieli E, Khunti K, Liebl A, Baeres FM, Svendsen AL, Ross SA, SOLVE Study Group.
    Diabetol Metab Syndr; 2013 Oct 02; 5(1):56. PubMed ID: 24499517
    [Abstract] [Full Text] [Related]

  • 53. Efficacy and safety of insulin detemir.
    Raskin P.
    Endocrinol Metab Clin North Am; 2007 Aug 02; 36 Suppl 1():21-32. PubMed ID: 17881329
    [Abstract] [Full Text] [Related]

  • 54. Patient characteristics and 6-month dose of basal insulin associated with HbA1c achievement <7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment (ORBIT).
    Gao L, Zhang P, Weng J, Lu J, Guo X, Jia W, Yang W, Zou D, Zhou Z, Pan C, Gao Y, Li X, Zhu D, Wu Y, Garg SK, Ji L.
    J Diabetes; 2020 Sep 02; 12(9):668-676. PubMed ID: 32329194
    [Abstract] [Full Text] [Related]

  • 55. Exenatide Once Weekly: Effectiveness, Tolerability, and Discontinuation Predictors in a Real-world Setting.
    Di Dalmazi G, Coluzzi S, Baldassarre MPA, Sorbo SE, Dell'Aquila S, Febo F, Ginestra F, Graziano G, Rossi MC, Consoli A, Formoso G.
    Clin Ther; 2020 Sep 02; 42(9):1738-1749.e1. PubMed ID: 32753164
    [Abstract] [Full Text] [Related]

  • 56. Clinical safety of insulin detemir in patients with Type 2 diabetes in the Gulf countries: The multicenter, noninterventional, open-label LevSafe study.
    El Shiekh AR, Farrag HA, Ashour T, Alshali KZ, AbdelFattah W.
    Indian J Endocrinol Metab; 2016 Sep 02; 20(4):443-50. PubMed ID: 27366709
    [Abstract] [Full Text] [Related]

  • 57. Hypoglycemia affects the changes in endothelial progenitor cell levels during insulin therapy in type 2 diabetic patients.
    Fadini GP, Albiero M, Vigili de Kreutzenberg S, Avogaro A.
    J Endocrinol Invest; 2015 Jul 02; 38(7):733-8. PubMed ID: 25722222
    [Abstract] [Full Text] [Related]

  • 58. Effect of basal insulin therapy on vascular endothelial function and adipokine profiles in people with Type 2 diabetes.
    Makino H, Tanaka A, Hosoda H, Koezuka R, Tochiya M, Ohata Y, Tamanaha T, Miyamoto Y, Kangawa K, Kishimoto I.
    Diabet Med; 2016 Dec 02; 33(12):1737-1743. PubMed ID: 27150701
    [Abstract] [Full Text] [Related]

  • 59. Rate of Inpatient Hypoglycemia Following a 1:1 Dose Interchange Between Concentrated Insulin Glargine to Insulin Detemir.
    Wulfe SD, Janzen KM, Addison J, Kelley D.
    Ann Pharmacother; 2023 May 02; 57(5):513-520. PubMed ID: 35993253
    [Abstract] [Full Text] [Related]

  • 60. Clinical experience with insulin detemir in patients with type 2 diabetes from the near East countries.
    Echtay A, Tsur A, Hasan MI, Abu-Hijleh MO, Al Khatib N, Andari E, Atallah P, Qureshi S, Zafar J, Sandalci L, Ademogulları A, Haddad J, Dagan B.
    Diabetes Ther; 2013 Dec 02; 4(2):399-408. PubMed ID: 24108581
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.